Cerus Corporation (NASDAQ: CERS) today announced financial results for the fourth quarter and year ended December 31, 2014.
“In the past several months, we have delivered two US approvals and our first two US customers, two successful Red Blood Cell clinical trials, and have raised more than $75 million in net proceeds to strengthen our balance sheet. These achievements position us to enter the U.S. market this year with INTERCEPT platelets and plasma, and to pursue CE mark approval for INTERCEPT red cells as early as 2016,” said William ‘Obi‘ Greenman, Cerus’ president and chief executive officer.
Help employers find you! Check out all the jobs and post your resume.
